ClinicalTrials.gg
Status unknownNCT04173312Updated Feb 23, 2022

Efficacy of Local Anesthetic Through Continuous Infusion

A Phase 3 interventional study of Bupivacaine infusion and Saline in Pain Control, sponsored by Ascension Health. Status unknown at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-23.

Sponsored by Ascension Health · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Efficacy of using continuous infusion of local anesthetic for post operative pain control following laparotomy.

Read the detailed description

This study will evaluate the benefits of placing an analgesic pain pump in laparotomy incisions with the addition of intravenous/oral pain medications as needed versus using solely intravenous and oral pain medications as needed for post-operative pain management. The goal of this study will be to decrease the usage of narcotics in post-operative laparotomy patients by providing local incision pain relief. This will be a double blinded randomized control study with placebo with two groups of patients: One with a local anesthetic infusion pump filled with Bupivacaine, a local anesthetic, after laparotomy and the other group with an infusion pump filled with normal saline. The pain pumps will be placed in the OR. Post-operatively, all patients will have the standard pain regimen available to them during their stay. Surgeons will monitor the patient for 4 days post-operatively and the infusion pain pump will be removed on post-operative day 4. Investigator will then look back through each patient's records and gather the amount of pain medications that they requested during their stay. Both groups will then have their data collected in the same manner and placed for data analysis. - The standard pain regimen will include a morphine IV 4mg every 4 hours and Hydrocodone-acetominophen 5/325 Q6H PRN. If a patient controlled analgesia infusion pump is needed this will be considered a need for increase in pain management. Every patient will be started on this pain regimen post operatively. During their stay, If the patient requires an increase in their pain medication, the supervising attending will determine which drug will be added in improve their pain. At the end of the patients stay, the amount of narcotic usage will be compiled and turned into morphine equivalents in order to compare them with the control group.

02

Conditions studied

  • Pain Control

Keywords

  • local anesthetic
  • continuous infusion
  • pain control
03

In context

Lead sponsor

Ascension Health is the lead sponsor of 21 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients scheduled for elective laparotomy

Exclusion criteria

Exclusion Criteria:

  • Emergency laparotomy
  • Pregnancy
  • Patients on chronic pain medication
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    Infused analgesic

    Patients will be assigned to receive local anesthetic through continuous infusion by pump.

    Combination Product: Bupivacaine infusion

  • Placebo comparator
    Infused saline

    Patients will be assigned to receive saline through continuous infusion by pump.

    Combination Product: Saline

Interventions

  • Combination productBupivacaine infusion

    Local systemic Infusion of anesthetic

  • Combination productSaline

    Local systemic infusion of saline

06

What researchers measure

Primary outcomes

  1. Self Reported Pain

    Patient reported pain rating on the Visual Analog Scale (VAS) for Pain. Pain intensity is rated on a scale of 0 to 100. It is anchored by 0 for no pain and 100 for worst pain ever.

    Time frame: 5 days

07

Study locations

1 of 1 sites recruiting
  • Ascension Genesys Hospital
    Grand Blanc, Michigan 48439, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2021 (actual). Primary completion is estimated for Jan 2023, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2019
First posted
Nov 21, 2019
StartActual
Jan 4, 2021
Primary completionEst.
Jan 2023
CompletionEst.
Dec 2023
Last update
Feb 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04173312
Lead sponsor
Ascension Health
Responsible party
Tarik Wasfie, MD (Principle Investigator, Ascension Health) — Principal investigator
First posted
Nov 21, 2019
Start date
Jan 4, 2021
Primary completion
Jan 2023 (estimated)
Completion
Dec 2023 (estimated)
Last update
Feb 23, 2022

Study contacts

Tarik Wasfie, MD
Contact
twasfie@gmail.com
8108539900
Kimberly Barber, PhD
Contact
kimberly.barber@ascension.org
8106067724
Tarik Wasfie, MD
principal investigator · Ascension Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupivacaine

Start the discussion